Does the CSL share price fall finally make it a no-brainer buy?

Could shares in the healthcare giant really offer 22% upside right now?

| More on:
A scientist examining test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price has come off recent highs, falling 9% from its February peak to trade at $286.18 today
  • Meanwhile, the company appears to be gearing up to grow following a rough few years amid the pandemic
  • And plenty of brokers are also bullish, with one tipping the stock to reach $350 a share

CSL Limited (ASX: CSL) is the market's most expensive company on a share price basis, with each of its stocks setting an investor back $286.18 at the time of writing.

But it's recently come off a peak. The CSL share price has dumped around 9% since posting a 15-month high in February, topping out at $314.28.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL1 Jan 202328 Mar 2023Zoom ▾9 Jan23 Jan6 Feb20 Feb6 Mar20 MarJan '23Jan '23Feb '23Feb '23Mar '23Mar '23www.fool.com.au

The company operates its Behring medicines business, its Vifor nephrology leg, its Seqirus influenza vaccines operation, and its plasma collection business.

And many brokers are tipping those businesses to grow amid rising demand, a productive research and development pipeline, and increasing plasma yields.

Indeed, one expert is forecasting the CSL share price to gain 22%. Though, not all are so bullish.

Could that mean the S&P/ASX 200 Index (ASX: XJO) biotechnology giant is finally a no-brainer buy? Let's take a closer look.

CSL share price hit hard by COVID-19

The CSL share price surged around 100% between 2018 and 2020. However, such growth slowed amid the onset of the pandemic.

Efforts to reduce the spread of COVID-19 saw the company's plasma collections tumble. Meanwhile, it embarked on an ultimately unsuccessful mission to create a vaccine for the virus.

It also underwent the $16 billion acquisition of Vifor, for which it completed a $6.3 billion capital raise in 2021.

Looking forward

Fortunately, things look to have bounced back for the ASX 200 company.

It posted record plasma collection last half, helping it achieve a US$1.6 billion profit. That's expected to come in at between US$2.7 billion and US$2.8 billion for the full year.

It's forecasting growth in plasma collections while its Hemgenix gene therapy product is expected to be launched in the United States shortly.

Finally, the integration of Vifor is said to be well advanced with delivery of synergies on schedule.

 Is CSL a buy right now?

 So, is CSL a no-brainer buy at its current share price?

Top broker Citi appears to think so. It has a buy rating and a $350 price target on the stock, my Fool colleague James reports. Citi tips the company's growth to be born from rising demand and a productive pipeline.

Meanwhile, Macquarie is expecting big things from the company's plasma collection yields, slapping CSL stock with an add rating and a $340 price target.

Rounding out the bulls is Morgans. It tips the stock to rise to $337.92 and has branded it with an add rating.

But not everyone is quite so hopeful.

Goldman Sachs is neutral on CSL shares, predicting that they'll rise to $314. The broker remains unsure of the company's path to margin recovery and is unconvinced of its valuation.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »